The new facility is aimed to boost the company’s local manufacturing capability to handle increasing demand in China for its peripheral neuropathy treatment Methycobal injection in expectation of sustained future growth in the market.
It is built on an 134,000m² lot in the Suzhou Industrial Park which was newly purchased by Eisai for the construction.
This plant will serve as the company’s new base for parenteral manufacturing and will initially be equipped with a production line for Methycobal injection that has the capacity to manufacture about maximum of 60 million ampoules per year.
In addition, the company intends to expand the role of its new facility in future to function as a global supply center of injection products for a range of markets including the rest of Asia and Latin America.